{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:57:59Z","timestamp":1783040279129,"version":"3.54.6"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"IMPACT Study was supported by BIOTRONIK, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Atrial high rate episodes (AHREs) are associated with increased risks of thromboembolism and cardiovascular mortality. However, the clinical characteristics of patients developing AHRE of various durations are not well studied.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>This was an ancillary analysis of the multicentre, randomized IMPACT trial. In the present analysis, we classified patients according to the duration of AHRE \u22646\u2009min, &amp;gt;6\u2009min to \u22646\u2009h, &amp;gt;6 to \u226424\u2009h and &amp;gt;24\u2009h, and investigated the association between clinical factors and the development of each duration of AHRE. Of 2718 patients included in the trial, 945 (34.8%) developed AHRE. The incidence rates of each AHRE duration category were 5.4\/100, 12.0\/100, 6.8\/100, and 3.3\/100 patient-years, respectively. The incidence rates of AHRE &amp;gt;6\u2009h were significantly higher in patients at high risk of thromboembolism (CHADS2 score \u22653) compared to those at low risk (CHADS2 score 1 or 2). Using Cox regression analysis, age \u226565\u2009years and history of atrial fibrillation (AF) and\/or atrial flutter (AFL) were risk factors for AHRE &amp;gt;6\u2009min. In addition, hypertension was associated with AHRE &amp;gt;24\u2009h (hazard ratio 2.13, 95% confidence interval 1.24\u20133.65, P\u2009=\u20090.006).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Atrial high rate episode &amp;gt;6\u2009min to \u22646\u2009h were most prevalent among all AHRE duration categories. Longer AHREs were more common in patients at risk of thromboembolism. Age and history of AF\/AFL were risk factors for AHRE &amp;gt;6\u2009min. Furthermore, hypertension showed a strong impact on the development of AHRE &amp;gt;24\u2009h rather than age.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/europace\/euab186","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T03:14:03Z","timestamp":1625541243000},"page":"375-383","source":"Crossref","is-referenced-by-count":23,"title":["Characteristics of patients with atrial high rate episodes detected by implanted defibrillator and resynchronization devices"],"prefix":"10.1093","volume":"24","author":[{"given":"Kazuo","family":"Miyazawa","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana Chuo-ku, Chiba 260-8677, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6357-5213","authenticated-orcid":false,"given":"Daniele","family":"Pastori","sequence":"additional","affiliation":[{"name":"Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Piazzale Aldo Moro, Rome 5 00185, Italy"},{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Thomas Drive, Liverpool L14 3PE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, 41 Mall Road Burlington, MA 01805, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim K","family":"Choucair","sequence":"additional","affiliation":[{"name":"Heart and Rhythm Institute of South Texas, 8122 Datapoint Dr, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L","family":"Halperin","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, Mount Sinai Heart, 1 Gustave L. Levy Pl, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Thomas Drive, Liverpool L14 3PE, UK"},{"name":"Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Fredrik Bajers Vej 7K, Aalborg \u00d8st 9220, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the IMPACT Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"2022030307595600200_euab186-B1","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jacc.2015.06.1314","article-title":"Incidence of atrial fibrillation and relationship with cardiovascular events, heart failure, and mortality: a community-based study from the Netherlands","volume":"66","author":"Vermond","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022030307595600200_euab186-B2","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1056\/NEJMoa1311376","article-title":"Atrial fibrillation in patients with cryptogenic stroke","volume":"370","author":"Gladstone","year":"2014","journal-title":"N Engl J Med"},{"key":"2022030307595600200_euab186-B3","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1161\/hs1101.098524","article-title":"Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German Stroke Data Bank","volume":"32","author":"Grau","year":"2001","journal-title":"Stroke"},{"key":"2022030307595600200_euab186-B4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1105575","article-title":"Subclinical atrial fibrillation and the risk of stroke","volume":"366","author":"Healey","year":"2012","journal-title":"N Engl J Med"},{"key":"2022030307595600200_euab186-B5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrcardio.2017.94","article-title":"Management of atrial high-rate episodes detected by cardiac implanted electronic devices","volume":"14","author":"Freedman","year":"17","journal-title":"Nat Rev Cardiol"},{"key":"2022030307595600200_euab186-B6","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1007\/s00392-019-01432-y","article-title":"Atrial high rate episodes in patients with cardiac implantable electronic devices: implications for clinical outcomes","volume":"108","author":"Miyazawa","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"2022030307595600200_euab186-B7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s00392-019-01493-z","article-title":"Atrial high-rate episodes and risk of major adverse cardiovascular events in patients with cardiac implantable electronic devices","volume":"109","author":"Pastori","year":"20","journal-title":"Clin Res Cardiol"},{"key":"2022030307595600200_euab186-B8","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.hrthm.2014.08.019","article-title":"Newly detected atrial high rate episodes predict long-term mortality outcomes in patients with permanent pacemakers","volume":"11","author":"Gonzalez","year":"2014","journal-title":"Heart Rhythm"},{"key":"2022030307595600200_euab186-B9"},{"key":"2022030307595600200_euab186-B10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2022030307595600200_euab186-B11","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s00392-018-1244-0","article-title":"Inflammation and the risk of atrial high-rate episodes (AHREs) in patients with cardiac implantable electronic devices","volume":"107","author":"Pastori","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"2022030307595600200_euab186-B12","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/eurheartj\/ehv115","article-title":"Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices","volume":"36","author":"Martin","year":"2015","journal-title":"Eur Heart J"},{"key":"2022030307595600200_euab186-B13","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"88","journal-title":"Biometrics"},{"key":"2022030307595600200_euab186-B14","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/europace\/euz172","article-title":"Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence","volume":"21","author":"Bertaglia","year":"2019","journal-title":"Europace"},{"key":"2022030307595600200_euab186-B15","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/eurheartj\/ehx042","article-title":"Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT","volume":"38","author":"Van Gelder","year":"17","journal-title":"Eur Heart J"},{"key":"2022030307595600200_euab186-B16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ahj.2017.04.008","article-title":"Rationale and design of the apixaban for the reduction of thrombo-embolism in patients with device-detected sub-clinical atrial fibrillation (ARTESiA) trial","volume":"189","author":"Lopes","year":"2017","journal-title":"Am Heart J"},{"key":"2022030307595600200_euab186-B17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ahj.2017.04.015","article-title":"Probing oral anticoagulation in patients with atrial high rate episodes: rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial","volume":"190","author":"Kirchhof","year":"2017","journal-title":"Am Heart J"},{"key":"2022030307595600200_euab186-B18","doi-asserted-by":"crossref","first-page":"e009509","DOI":"10.1161\/JAHA.118.009509","article-title":"Digoxin and platelet activation in patients with atrial fibrillation: in vivo and in vitro study","volume":"7","author":"Pastori","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2022030307595600200_euab186-B19","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.hrthm.2012.03.017","article-title":"Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT","volume":"9","author":"Kaufman","year":"12","journal-title":"Heart Rhythm"},{"key":"2022030307595600200_euab186-B20","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1016\/j.jacc.2019.09.050","article-title":"Natural history of subclinical atrial fibrillation detected by implanted loop recorders","volume":"74","author":"Diederichsen","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022030307595600200_euab186-B21","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1016\/j.jacc.2011.08.045","article-title":"CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation","volume":"58","author":"Chao","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2022030307595600200_euab186-B22","doi-asserted-by":"crossref","first-page":"e77653","DOI":"10.1371\/journal.pone.0077653","article-title":"Relationship of CHA2DS2-VASc and CHADS2 score to left atrial remodeling detected by velocity vector imaging in patients with atrial fibrillation","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"2022030307595600200_euab186-B23","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.amjmed.2016.02.029","article-title":"Usefulness of CHADS2 and CHA2DS2-VASc scores in the prediction of new-onset atrial fibrillation: a population-based study","volume":"129","author":"Saliba","year":"2016","journal-title":"Am J Med"}],"container-title":["EP Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/24\/3\/375\/42684445\/euab186.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/24\/3\/375\/42684445\/euab186.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T08:18:16Z","timestamp":1646295496000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/24\/3\/375\/6356790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,8,24]]},"published-print":{"date-parts":[[2022,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euab186","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,8,24]]}}}